Table 2 Antibiotic regimens therapy during hospitalization
Antimicrobial | Total (n = 108) | Nonsurvivor (n = 75) | Survivor (n = 33) |
|---|---|---|---|
Antibiotic usage during hospitalization, n (%) | |||
Carbapenem | 92 (85.2) | 66 (88.0) | 26 (78.8) |
Cefoperazone/sulbactam | 75 (69.4) | 49 (65.3) | 26 (78.8) |
Piperacillin/tazobactam | 30 (27.8) | 18 (24.0) | 12 (36.4) |
Tigecycline | 49 (45.4) | 33 (44.0) | 16 (48.5) |
Polymyxin B | 8 (7.4) | 4 (5.3) | 4 (12.1) |
Antibiotic regimens after positive blood culture, n (%) | |||
Carbapenem | 16 (14.8) | 12 (16.0) | 4 (12.1) |
Cefoperazone/sulbactam | 14 (13.0) | 10 (13.3) | 4 (12.1) |
Tigecycline | 6 (5.6) | 6 (8.0) | 0 (0) |
Carbapenem + Tigecycline | 9 (8.3) | 9 (12.0) | 0 (0) |
Cefoperazone/sulbactam + Tigecycline | 28 (25.9) | 13 (17.3) | 15 (45.5) |
Polymyxin B + Tigecycline | 5 (4.6) | 3 (4.0) | 2 (6.1) |